Mixed Results With Pemafibrate in Patients With Type 2 Diabetes

(MedPage Today) -- CHICAGO – The incidence of cardiovascular (CV) events did not budge for patients with type 2 diabetes (T2D) who received pemafibrate versus placebo, although the study agent did cut triglycerides and various cholesterol...